Blood Pressure Lowering and Safety Improvements with Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury

Hypertension

Volumn 70, Issue 3, 2017, Pages 566-576

  Mullick, Adam E ^a   Yeh, Steve T ^a   Graham, Mark J ^a   Engelhardt, Jeffery A ^a   Prakash, Thazha P ^a   Crooke, Rosanne M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

acute kidney injury; angiotensin II; angiotensinogen; blood pressure; hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSINOGEN; ANGIOTENSINOGEN ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR 11; CAPTOPRIL; LIPOPROTEIN A; LOSARTAN; N ACETYLGALACTOSAMINE; PREALBUMIN; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD PRESSURE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; GLOMERULUS BASEMENT MEMBRANE; HYPERTENSION; INFLAMMATORY CELL; KIDNEY; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROPERITONEAL FAT; SINGLE DRUG DOSE; SODIUM RESTRICTION; SPONTANEOUSLY HYPERTENSIVE RAT; TELEMETRY; TREATMENT DURATION; ACUTE KIDNEY INJURY; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; HYPERTENSION; KIDNEY; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, INBRED SHR; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 85024490412     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.117.09755     Document Type: Article

References (33)

1. Williams B, Drug discovery in renin-angiotensin system intervention: past and future. Ther Adv Cardiovasc Dis 2016 10 118 125. doi: 10.1177/1753944716642680
2. Nobakht N, Kamgar M, Rastogi A, Schrier RW, Limitations of angiotensin inhibition. Nat Rev Nephrol 2011 7 356 359. doi: 10.1038/nrneph.2011.29
3. Bomback AS, Klemmer PJ, The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007 3 486 492. doi: 10.1038/ncpneph0575
4. Narayan H, Webb DJ, New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. Curr Hypertens Rep 2016 18 34. doi: 10.1007/s11906-016-0643-8
5. Roig E, Perez-Villa F, Morales M, Jiménez W, Orús J, Heras M, Sanz G, Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000 21 53 57. doi: 10.1053/euhj.1999.1740
6. Ferrario CM, Ahmad S, Varagic J, Cheng CP, Groban L, Wang H, Collawn JF, Dell Italia LJ, Intracrine angiotensin II functions originate from noncanonical pathways in the human heart. Am J Physiol Heart Circ Physiol 2016 311 H404 H414. doi: 10.1152/ajpheart.00219.2016
7. Lu H, Wu C, Howatt DA, Balakrishnan A, Moorleghen JJ, Chen X, Zhao M, Graham MJ, Mullick AE, Crooke RM, Feldman DL, Cassis LA, Vander Kooi CW, Daugherty A, Angiotensinogen exerts effects independent of angiotensin II. Arterioscler Thromb Vasc Biol 2016 36 256 265. doi: 10.1161/ATVBAHA.115.306740
8. Yiannikouris F, Wang Y, Shoemaker R, Larian N, Thompson J, English VL, Charnigo R, Su W, Gong M, Cassis LA, Deficiency of angiotensinogen in hepatocytes markedly decreases blood pressure in lean and obese male mice. Hypertension 2015 66 836 842. doi: 10.1161/HYPERTENSIONAHA.115.06040
9. Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, Nishiyama A, Ichikawa I, Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol 2012 23 1181 1189. doi: 10.1681/ASN.2011121159
10. Navar LG, Translational studies on augmentation of intratubular renin-angiotensin system in hypertension. Kidney Int Suppl 2013 3 321 325. doi: 10.1038/kisup.2013.67
11. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH, Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013 346 f360
12. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH, Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res 2015 116 960 975. doi: 10.1161/CIRCRESAHA.116.303587
13. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S, Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016 388 2239 2253. doi: 10.1016/S0140-6736(16)31009-1
14. Prakash TP, Yu J, Migawa MT, Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J Med Chem 2016 59 2718 2733. doi: 10.1021/acs.jmedchem.5b01948
15. Donner AJ, Yeh ST, Hung G, Graham MJ, Crooke RM, Mullick AE, CD40 generation 2.5 antisense oligonucleotide treatment attenuates doxorubicin-induced nephropathy and kidney inflammation. Mol Ther Nucleic Acids 2015 4 e265. doi: 10.1038/mtna.2015.40
16. Varagic J, Frohlich ED, Susic D, Ahn J, Matavelli L, Lopez B, Diez J, At1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. Am J Physiol Heart Circ Physiol 2008 294 H853 H 858
17. Griffiths CD, Morgan TO, Delbridge LM, Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake. J Hypertens 2001 19 2087 2095
18. Richer-Giudicelli C, Domergue V, Gonzalez MF, Messadi E, Azizi M, Giudicelli JF, Ménard J, Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt. J Hypertens 2004 22 619 627
19. Engelhardt JA, Comparative renal toxicopathology of antisense oligonucleotides. Nucleic Acid Ther 2016 26 199 209. doi: 10.1089/nat.2015.0598
20. Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, Takano K, Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002 40 28 33
21. Susic D, Frohlich ED, Kobori H, Shao W, Seth D, Navar LG, Salt-induced renal injury in shrs is mediated by at1 receptor activation. J Hypertens 2011 29 716 723
22. Susic D, Fares H, Frohlich ED, Telmisartan prevents excess-salt-induced exacerbated (malignant) hypertension in spontaneously hypertensive rats. J Cardiovasc Pharmacol Ther 2013 18 126 132
23. Saigusa T, Dang Y, Mullick AE, Yeh ST, Zile MR, Baicu CF, Bell PD, Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. FASEB J 2016 30 370 379. doi: 10.1096/fj.15-279299
24. Phillips MI, Gene therapy for hypertension: the preclinical data. Hypertension 2001 38 3 pt 2 543 548
25. Olearczyk J, Gao S, Eybye M, Yendluri S, Andrews L, Bartz S, Cully D, Tadin-Strapps M, Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension. Hypertens Res 2014 37 405 412. doi: 10.1038/hr.2013.155
26. Ferrario CM, Mullick AE, Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease [published online ahead of print May 29, 2017]. Pharmacol Res. doi: 10.1016/j.phrs.2017.05.020. http://www.sciencedirect.com/science/article/pii/S1043661817303456
27. Wu C, Lu H, Cassis LA, Daugherty A, Molecular and pathophysiological features of angiotensinogen: a mini review. N Am J Med Sci 2011 4 183 190
28. Bohlender J, Ménard J, Ganten D, Luft FC, Angiotensinogen concentrations and renin clearance: implications for blood pressure regulation. Hypertension 2000 35 780 786
29. Navar LG, Satou R, Gonzalez-Villalobos RA, The increasing complexity of the intratubular renin-angiotensin system. J Am Soc Nephrol 2012 23 1130 1132. doi: 10.1681/ASN.2012050493
30. Burke M, Pabbidi MR, Farley J, Roman RJ, Molecular mechanisms of renal blood flow autoregulation. Curr Vasc Pharmacol 2014 12 845 858
31. Schnermann J, Levine DZ, Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol 2003 65 501 529. doi: 10.1146/annurev.physiol.65.050102.085738
32. Pohl M, Kaminski H, Castrop H, Bader M, Himmerkus N, Bleich M, Bachmann S, Theilig F, Intrarenal renin angiotensin system revisited: role of megalin-dependent endocytosis along the proximal nephron. J Biol Chem 2010 285 41935 41946. doi: 10.1074/jbc.M110.150284
33. Rohrwasser A, Morgan T, Dillon HF, Zhao L, Callaway CW, Hillas E, Zhang S, Cheng T, Inagami T, Ward K, Terreros DA, Lalouel JM, Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 1999 34 1265 1274